|
|
|
|
|
07.01.26 - 23:03
|
Correction: Transactions of Managers and Closely Associated Persons (GlobeNewswire EN)
|
|
|
Attached are copies of two filings with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons. ATP Holdings ehf. announced two transactions, an acquisition of 4,812,257 shares in Alvotech on December 17, 2025, and a sale of 2,110,640 shares in Alvotech on December 19, 2025. The transaction price in both cases was SEK 44.06 per share....
|
|
|
06.01.26 - 21:06
|
Transactions of Managers and Closely Associated Persons (GlobeNewswire EN)
|
|
|
Attached is a copy of a filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons, announcing the acquisition of 7,007,321 shares in Alvotech by Alvogen Lux Holdings S.a. r.l. at a price of SEK 44.06 per share. The date of the transaction was December 17, 2025. ...
|
|
|
06.01.26 - 21:03
|
Transactions of Managers and Closely Associated Persons (GlobeNewswire EN)
|
|
|
Attached is a copy of two filings with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons, announcing the acquisition of shares in Alvotech by ATP Holdings ehf. The shares were aquired in two transactions, 4,812,257 shares on December 17, 2025 and 2,110,640 shares on December 19, 2025. The transaction price was SEK 44.06 per share....
|
|
|
|
|
|
|
|
|
31.12.25 - 22:36
|
Alvotech Secures Term Loan Facility of USD 100 Million (GlobeNewswire EN)
|
|
|
REYKJAVIK, ICELAND (December 31, 2025) — Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced a USD 100 million senior term loan facility with maturity in December 2027 aimed at strengthening liquidity and supporting the execution of Alvotech's strategic priorities in 2026....
|
|
|
|
|
|
|
22.12.25 - 21:30
|
Alvotech′s Financial Calendar for 2026 (GlobeNewswire EN)
|
|
|
Alvotech (NASDAQ: ALVO, ALVO SDB) today publishes its financial calendar for 2026. Annual or interim results are released on the dates specified below, after the close of U.S. markets. An investor call is held on the following day, after release of the results....
|
|
|
|
|
22.12.25 - 08:09
|
Alvotech announces European launch of first-in-market biosimilar to Simponi® (golimumab) globally by partner Advanz Pharma (GlobeNewswire EN)
|
|
|
REYKJAVIK, Iceland, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that launches are underway in Europe for Gobivaz® (golimumab), Alvotech's biosimilar to Simponi® (golimumab), also known as AVT05 (prefilled syringe and autoinjector). Gobivaz is the first marketed biosimilar to Simponi worldwide. It is being commercialized exclusively in Europe by Alvotech's partner, Advanz Pharma Holdco Limited (“Advanz Pharma”)....
|
|
|
|
|
|
|
19.12.25 - 09:42
|
Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea® (GlobeNewswire EN)
|
|
|
REYKJAVIK, Iceland and TEL AVIV, Israel, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that they have reached a settlement and license agreement with Regeneron Pharmaceuticals Inc. concerning the launch of AVT06, Alvotech's proposed biosimilar to Eylea® (aflibercept) in the United States. The settlement grants a license entry date for AVT06 in the United States in the fourth quarter of 2026, or earlier under certain circumstances....
|
|
|
19.12.25 - 09:36
|
Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea® (GlobeNewswire EN)
|
|
|
REYKJAVIK, ICELAND & TEL AVIV, ISRAEL & PARSIPPANY, NJ (December 19, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that they have reached a settlement and license agreement with Regeneron Pharmaceuticals Inc. concerning the launch of AVT06, Alvotech's proposed biosimilar to Eylea® (aflibercept) in the United States. The settlement grants a license entry date for AVT06 in the United States in the fourth quarter of 2026, or earlier under certain circumstances. ...
|
|
|
19.12.25 - 09:33
|
Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea® (GlobeNewswire EN)
|
|
|
According to the settlement agreement, the proposed biosimilar to Eylea® (aflibercept) can be marketed in the U.S., if approved by the FDA, in the fourth quarter of 2026, or earlier under certain circumstances According to the settlement agreement, the proposed biosimilar to Eylea® (aflibercept) can be marketed in the U.S., if approved by the FDA, in the fourth quarter of 2026, or earlier under certain circumstances...
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
